9th TBPK – Presentations

  Session 1: Pharmacokinetics & pharmacodynamics of new & redeveloped TB drugs
Chair: Rob Aarnoutse
 
A new model for early clinical development of TB drugs and its application to Q203 and BTZ043
Dr. N. Heinrich, University of Munich, Germany
  Abstract presentations
 A model-based analysis to describe bedaquiline’s exposure-response relationship and predict the impact of drug-drug interactions
Dr. E. Svensson, Uppsala University, Sweden
 Population Pharmacokinetics of AZD5847 in Adults with Pulmonary Tuberculosis
Dr. C. Peloquin, University of Florida, USA
 Pharmacokinetic Modeling and Simulation of the Interaction between Moxifloxacin and Rifapentine in Healthy Volunteers
Dr. M. Imperial, Universiteit van Californië - San Francisco, USA
 Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin
Dr. R. Svensson, Uppsala University, Sweden
  Session 2: Pharmacokinetics & pharmacodynamics of existing TB drugs
Chair: Eric Nuermberger & Ulrika Simonsson
 

Rifampin vs. Rifapentine: a debate over the preferred rifamycin
Dr. C. Peloquin, University of Florida, USA

 
Rifampin vs. Rifapentine: a debate over the preferred rifamycin
Dr. K. Dooley, Johns Hopkins University, USA
  Abstract presentations
 Lung Tissue Concentrations of Pyrazinamide among Patients with Tuberculosis
Dr. R. Kempker, Emory University, USA
 Early interventions for diabetes related tuberculosis hasten sputum microbiological clearance in Virginia, USA
Dr. S. Heysell, University of Virginia, USA
 Sub-therapeutic concentrations of anti-tuberculosis drugs in children when treated according to indian dosing recommendation
Dr. B. Guiastrennec, Uppsala Universitet, Sweden
 A Need for altering Tuberculosis Dosing Regiments for patients with HIV-associated Tuberculous Meningitis
Dr. G. Aljayyoussi, Liverpool School of Tropical Medicine, United Kingdom
  Session 3: Population pharmacokinetics and pharmacokinetic-pharmacodynamic modelling
Chair: Helen McIlleron & Russell Kempker
 
Lost in translation: learning from preclinical data
Dr. G. Davies, University of Liverpool, United Kingdom
  Abstract presentations
 Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis
Dr. I. Gardner, Simcyp Limited, United Kingdom
 Application Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects
Dr. O. Hatley, Simcyp Limited, United Kingdom
 A translational modelling and simulations approach to exploit pre-clinical tuberculosis data
Dr. S. Wicha, Uppsala Universitet, Sweden
 The relationship between pyrazinamide pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 28 and PanACEA MAMS
Dr. K. Dooley, Johns Hopkins University, USA
  Session 4: Drug development and optimization: approaches and tools
Chair: Gerry Davies & Paolo Denti
 
Long acting (LA) drug delivery in TB treatment
Dr. A. Owen, University of Liverpool, United Kingdom
  Abstract presentations
 Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling
Dr. R. Rajoli, University of Liverpool, United Kingdom
 High drug tolerance of Mycobacterium tuberculosis in caseum
Dr. J. Sarathy, Rutgers, New Jersey Medical School, USA
 Rifapentine plus Isoniazid Eradicates Mycobacterium tuberculosis among Rhesus Macaques with Latent TB Infection
Dr. H. Blumberg, University of Liverpool, United Kingdom
 Exploration of Non-Replicating Mycobacterium Tuberculosis In Vitro System Through Mathematical Modelling
Dr. A. Schipani, University of Liverpool, United Kingdom